Emerging research suggests that magnetic resonance imaging (MRI) guidance may be more advantageous than computed tomography (CT) guidance for reducing the side effects of stereotactic body radiation therapy (SBRT) in the treatment of prostate cancer.
Results from the phase 3 randomized trial, recently published in JAMA Oncology, showed that MRI guidance for SBRT led to a significantly reduced acute grade 2 or greater genitourinary (GU) toxicity rate (24.4 percent) versus that of CT guidance (43.4 percent). Researchers also noted no acute grade 2 or greater gastrointestinal (GI) toxic effects with MRI guidance in comparison to a 10.5 percent toxicity rate for CT guidance.
In a recent video interview, lead study author Amar Kishan, M.D. called the MRIdian LINAC (ViewRay) a “major technological breakthrough” that allows physicians to combine continuous MRI imaging with a more targeted radiation delivery system for prostate cancer.
“The whole point of this scan is that it allows, at lower PSA levels, to detect where that (prostate recurrence) site is and helps us come up with a subsequent therapy that is most effective in those patients,” noted Dr. Helfand, who presented the research at the AUA conference. “It’s always a surprise when you have distant metastases … When that happens, that can definitely change how we think about treatment and the type of the treatment that patient will get.”
Results from the phase 3 randomized trial, recently published in JAMA Oncology, showed that MRI guidance for SBRT led to a significantly reduced acute grade 2 or greater genitourinary (GU) toxicity rate (24.4 percent) versus that of CT guidance (43.4 percent). Researchers also noted no acute grade 2 or greater gastrointestinal (GI) toxic effects with MRI guidance in comparison to a 10.5 percent toxicity rate for CT guidance.
In a recent video interview, lead study author Amar Kishan, M.D. called the MRIdian LINAC (ViewRay) a “major technological breakthrough” that allows physicians to combine continuous MRI imaging with a more targeted radiation delivery system for prostate cancer.
“The whole point of this scan is that it allows, at lower PSA levels, to detect where that (prostate recurrence) site is and helps us come up with a subsequent therapy that is most effective in those patients,” noted Dr. Helfand, who presented the research at the AUA conference. “It’s always a surprise when you have distant metastases … When that happens, that can definitely change how we think about treatment and the type of the treatment that patient will get.”
Source from:
www.diagnosticimaging.com by Jeff Hall
www.diagnosticimaging.com by Jeff Hall